Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
31 mars 2023 06h00 HE
|
Eledon Pharmaceuticals, Inc.
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft function observed in all three participants with mean eGFRs above 70...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
30 mars 2023 16h01 HE
|
Eledon Pharmaceuticals, Inc.
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
23 mars 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the fourth quarter and full...
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
23 mars 2023 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present two posters at the upcoming International...
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
08 févr. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
Eledon Pharmaceuticals Provides Business and Pipeline Updates
09 janv. 2023 08h31 HE
|
Eledon Pharmaceuticals, Inc.
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data...
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
21 déc. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion...
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
14 nov. 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S....
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
03 nov. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter...
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
24 oct. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...